# Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

> **NCT02107950** · PHASE2 · COMPLETED · sponsor: **SOTIO a.s.** · enrollment: 71 (actual)

## Conditions studied

- Ovarian Neoplasms
- Ovarian Cancer (OvCa)
- Ovarian Epithelial Cancer

## Interventions

- **BIOLOGICAL:** DCVAC/OvCa in parallel with chemotherapy
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT02107950
- **Lead sponsor:** SOTIO a.s.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-11
- **Final completion:** 2017-05-17
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2018-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107950, "Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02107950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*